Phio Pharmaceuticals (NASDAQ:PHIO) Director Ronald Todd Plott Purchases 18,300 Shares of Company Stock

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Director Ronald Plott purchased 18,300 shares of the firm’s stock in a transaction on Monday, November 9th. The shares were acquired at an average price of $0.83 per share, with a total value of $15,189.00. Following the purchase, the director directly owned 60,300 shares in the company, valued at $50,049. This represents a 43.57% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ronald Todd Plott also recently made the following trade(s):

• On Monday, September 28th, Ronald Plott bought 5,000 shares of Phio Pharmaceuticals stock. The shares were bought at an average cost of $1.03 per share, for a total transaction of $5,150.00.
• On Wednesday, August 19th, Ronald Plott bought 15,000 shares of Phio Pharmaceuticals stock. The stock was purchased at an average price of $1.14 per share, with a total value of $17,100.00.

Phio Pharmaceuticals Price Performance

Shares of NASDAQ PHIO traded up $0.01 during midday trading on Tuesday, reaching $0.85. The company’s stock had a trading volume of 37,487 shares, compared to its average volume of 1,315,510. The stock has a market capitalization of $9.87 million, a P/E ratio of -0.70 and a beta of 0.93. The firm has a 50 day moving average price of $0.96 and a 200-day moving average price of $1.08. Phio Pharmaceuticals Corp. has a 12-month low of $0.75 and a 12-month high of $1.88.

Phio Pharmaceuticals (NASDAQ:PHIO) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.36) EPS for the quarter, hitting the consensus estimate of ($0.36). On average, equities analysts predict that Phio Pharmaceuticals Corp. will post -1.45 EPS for the current year.

Analysts Set New Price Targets

PHIO has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Phio Pharmaceuticals in a report on Wednesday, August 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of Phio Pharmaceuticals in a report on Thursday, October 15th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $14.00.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a biotechnology company focused on developing cancer immunotherapies. The company’s programs are designed to enhance the immune system’s ability to recognize and destroy tumor cells, with an emphasis on treatments that may be administered directly to the tumor or used in combination with other therapies. Phio’s research is based on its INTASYL self-delivering RNA interference (RNAi) technology. The platform is intended to selectively silence genes involved in immune suppression and cancer progression without requiring a separate delivery vehicle.